Cargando…
Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
BACKGROUND: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018194/ https://www.ncbi.nlm.nih.gov/pubmed/29119933 http://dx.doi.org/10.2174/1570159X15666171109132650 |
_version_ | 1783334902660333568 |
---|---|
author | Miller, Elżbieta Morel, Agnieszka Redlicka, Justyna Miller, Igor Saluk, Joanna |
author_facet | Miller, Elżbieta Morel, Agnieszka Redlicka, Justyna Miller, Igor Saluk, Joanna |
author_sort | Miller, Elżbieta |
collection | PubMed |
description | BACKGROUND: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms. METHODS: Therefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases. RESULTS: The most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function. CONCLUSION: This article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented. |
format | Online Article Text |
id | pubmed-6018194 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-60181942018-11-01 Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis Miller, Elżbieta Morel, Agnieszka Redlicka, Justyna Miller, Igor Saluk, Joanna Curr Neuropharmacol Article BACKGROUND: Cognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms. METHODS: Therefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases. RESULTS: The most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function. CONCLUSION: This article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented. Bentham Science Publishers 2018-05 2018-05 /pmc/articles/PMC6018194/ /pubmed/29119933 http://dx.doi.org/10.2174/1570159X15666171109132650 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Miller, Elżbieta Morel, Agnieszka Redlicka, Justyna Miller, Igor Saluk, Joanna Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title_full | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title_fullStr | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title_full_unstemmed | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title_short | Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis |
title_sort | pharmacological and non-pharmacological therapies of cognitive impairment in multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018194/ https://www.ncbi.nlm.nih.gov/pubmed/29119933 http://dx.doi.org/10.2174/1570159X15666171109132650 |
work_keys_str_mv | AT millerelzbieta pharmacologicalandnonpharmacologicaltherapiesofcognitiveimpairmentinmultiplesclerosis AT morelagnieszka pharmacologicalandnonpharmacologicaltherapiesofcognitiveimpairmentinmultiplesclerosis AT redlickajustyna pharmacologicalandnonpharmacologicaltherapiesofcognitiveimpairmentinmultiplesclerosis AT millerigor pharmacologicalandnonpharmacologicaltherapiesofcognitiveimpairmentinmultiplesclerosis AT salukjoanna pharmacologicalandnonpharmacologicaltherapiesofcognitiveimpairmentinmultiplesclerosis |